| 臺大學術典藏 |
2021-05-03T09:17:12Z |
Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in life
|
Hsieh C.-C.;Chao-Chi Ho;Lin Z.-Z.;Yu C.-J.;Jow G.-M.;Huang F.-Y.;Shih J.-Y.;Hsiao F.-H.; Hsieh C.-C.; CHAO-CHI HO; Lin Z.-Z.; Yu C.-J.; Jow G.-M.; Huang F.-Y.; Shih J.-Y.; Hsiao F.-H. |
| 臺大學術典藏 |
2021-05-03T09:17:10Z |
Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer
|
Hsu C.-L.; Tsai T.-H.; Huang C.-K.; Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Ruan S.-Y.; Chen K.-Y.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2021-05-02T04:37:08Z |
Effect of β-Blocker in Treatment-Na?ve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
|
Chang C.-H.; Lee C.-H.; Ko J.-C.; Chang L.-Y.; Lee M.-C.; Zhang J.-F.; JANN-YUAN WANG; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-05-02T04:37:07Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; JANN-YUAN WANG; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-05-02T03:56:38Z |
Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer
|
Hsu C.-L.; Tsai T.-H.; Huang C.-K.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Ruan S.-Y.; Chen K.-Y.; Shih J.-Y.; PAN-CHYR YANG |
| 臺大學術典藏 |
2021-05-02T03:29:26Z |
Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in life
|
Hsieh C.-C.;Ho C.-C.;Lin Z.-Z.;Chong-Jen Yu;Jow G.-M.;Huang F.-Y.;Shih J.-Y.;Hsiao F.-H.; Hsieh C.-C.; Ho C.-C.; Lin Z.-Z.; CHONG-JEN YU; Jow G.-M.; Huang F.-Y.; Shih J.-Y.; Hsiao F.-H. |
| 臺大學術典藏 |
2021-05-02T03:29:25Z |
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
|
Wu S.-G.;Chong-Jen Yu;Yang J.C.-H.;Shih J.-Y.; Wu S.-G.; CHONG-JEN YU; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-05-02T03:29:24Z |
Effect of β-Blocker in Treatment-Na?ve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
|
Chang C.-H.;Lee C.-H.;Ko J.-C.;Chang L.-Y.;Lee M.-C.;Zhang J.-F.;Wang J.-Y.;Shih J.-Y.;Chong-Jen Yu; Chang C.-H.; Lee C.-H.; Ko J.-C.; Chang L.-Y.; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; Shih J.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2021-05-02T03:29:21Z |
Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1
|
Chung K.-P.; Huang Y.-L.; Chen Y.-J.; Juan Y.-H.; Hsu C.-L.; Nakahira K.; Huang Y.-T.; Lin M.-W.; Wu S.-G.; Shih J.-Y.; Chang Y.-L.; CHONG-JEN YU |
| 臺大學術典藏 |
2021-05-02T03:29:21Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; CHONG-JEN YU |
| 朝陽科技大學 |
2021-05 |
Removal of soluble microbial products and dyes using heavy metal wastes decorated on eggshell
|
Chen, S.-J.; Shih, J.-Y.; Koyande, A.K.; Liu, B.-L.; Chang, Y.-K.; 劉炳嵐; Chai, W.S.; Lin, T.-Y. |
| 臺大學術典藏 |
2021-04-30T07:26:49Z |
Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer
|
Huang Y.-S.; JENNY LING-YU CHEN; Chen H.-M.; Yeh L.-H.; Shih J.-Y.; Yen R.-F.; Chang Y.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:26Z |
Primary pulmonary plasmacytoma with lobar consolidation: An unusual presentation
|
KUAN-YU CHEN; Wu H.-D.; Chang Y.-L.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:25Z |
Lung cancer in pregnancy: Report of two cases
|
KUAN-YU CHEN; Wang H.-C.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:19Z |
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
|
Shih J.-Y.; Gow C.-H.; Yu C.-J.; Yang C.-H.; Chang Y.-L.; Tsai M.-F.; Hsu Y.-C.; KUAN-YU CHEN; Su W.-P.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:17Z |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
|
Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; KUAN-YU CHEN; Lin Z.-Z.; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:15Z |
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer
|
Wu J.-Y.; Shih J.-Y.; Yang C.-H.; KUAN-YU CHEN; Ho C.-C.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:15Z |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
|
Huang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C.; KUAN-YU CHEN; Shih J.-Y.; Lin Z.-Z.; Yu C.-J.; Cheng A.-L.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:14Z |
Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer
|
Lee J.-H.; Yu C.-J.; KUAN-YU CHEN; Shih J.-Y.; Lin Y.-L.; Yang C.-H. |
| 臺大學術典藏 |
2021-04-29T05:09:14Z |
Octogenarians with advanced non-small cell lung cancer: Treatment modalities, survival, and prognostic factors
|
KUAN-YU CHEN; Chen J.-H.; Shih J.-Y.; Yang C.-H.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:12Z |
The prognostic value of the simplified comorbidity score in the treatment of small cell lung carcinoma
|
Kuo Y.-W.; Jerng J.-S.; Shih J.-Y.; KUAN-YU CHEN; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:12Z |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
|
Wu J.-Y.; Shih J.-Y.; KUAN-YU CHEN; Yang C.-H.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:11Z |
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed
|
Chen C.-Y.; Chang Y.-L.; Shih J.-Y.; Lin J.-W.; KUAN-YU CHEN; Yang C.-H.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:10Z |
Advanced non-small cell lung cancer in patients aged 45 years or younger: Outcomes and prognostic factors
|
Hsu C.-L.; KUAN-YU CHEN; Shih J.-Y.; Ho C.-C.; Yang C.-H.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:07Z |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Tsai T.-H.; Yang C.-Y.; Ho C.-C.; Liao W.-Y.; Jan I.-S.; KUAN-YU CHEN; Wang J.-Y.; Ruan S.-Y.; Yu C.-J.; Yang J.C.H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-04-29T05:09:07Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Liao W.-Y.; Chen J.-H.; Wu M.; Shih J.-Y.; KUAN-YU CHEN; Ho C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:09:06Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Lee J.-H.; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; KUAN-YU CHEN; Ho C.-C.; Laio W.-Y.; Yang P.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-04-29T05:09:04Z |
Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis
|
Hsu C.-L.; Chen J.-H.; KUAN-YU CHEN; Shih J.-Y.; Yang J.C.H.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:03Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Na?ve Lung Adenocarcinoma in Taiwan
|
Hsu K.-H.; Ho C.-C.; Hsia T.-C.; Tseng J.-S.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Chang G.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:03Z |
Estimated creatinine clearance rate is associated with the treatment effectiveness and toxicity of pemetrexed as continuation maintenance therapy for advanced nonsquamous non-small-cell lung cancer
|
Chen C.-Y.; Lin J.-W.; Huang J.-W.; KUAN-YU CHEN; Shih J.-Y.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:02Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Ho C.-C.; Hsia T.-C.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2021-04-29T05:08:57Z |
Outcomes of cancer therapy administered to treatment-na?ve lung cancer patients in the intensive care unit
|
Chen Y.-F.; Lin J.-W.; Ho C.-C.; Yang C.-Y.; Chang C.-H.; Huang T.-M.; Chen C.-Y.; KUAN-YU CHEN; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:56Z |
Expression of notch gene and its impact on survival of patients with resectable non-small cell lung cancer
|
Chen C.-Y.; Chen Y.-Y.; Hsieh M.-S.; Ho C.-C.; KUAN-YU CHEN; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:55Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; KUAN-YU CHEN; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:55Z |
Coexistence of the BRAF Mutation and EGFR Exon 20?Insertion in a Patient with Lung Adenocarcinoma
|
Chang L.-C.; KUAN-YU CHEN; Shih J.-Y.; Yu C.-J.; Hsieh M.-S. |
| 臺大學術典藏 |
2021-04-29T05:08:54Z |
Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression
|
Chen C.-Y.; Chen Y.-Y.; Chen J.J.W.; KUAN-YU CHEN; Ho C.-C.; Shih J.-Y.; Chang Y.-L.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:08:54Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; KUAN-YU CHEN; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:53Z |
Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?
|
Lim C.-K.; Wei Y.-F.; Tsai M.-S.; KUAN-YU CHEN; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:53Z |
Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum
|
Liao W.-Y.; Ho C.-C.; Tsai T.-H.; KUAN-YU CHEN; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:53Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C.; Xiao F.; Shih J.-Y.; Ho C.-C.; Chen Y.-F.; Tseng H.-M.; KUAN-YU CHEN; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; Kuo S.-H.; Cheng J.C.-H.; Yang P.-C.; Hsu F.-M. |
| 臺大學術典藏 |
2021-04-29T05:08:51Z |
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors
|
Chang L.-C.;Lim C.-K.;Chang L.-Y.;Kuan-Yu Chen;Shih J.-Y.;Yu C.-J.; Chang L.-C.; Lim C.-K.; Chang L.-Y.; KUAN-YU CHEN; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:51Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Kuan-Yu Chen;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; KUAN-YU CHEN; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:51Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Kuan-Yu Chen;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; Ho C.-C.; KUAN-YU CHEN; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:50Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Chen J.-S.;Liao W.-Y.;Shih J.-Y.;Yu C.-J.;Kuan-Yu Chen;Tsai T.-H.;Yang J.C.-H.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; Chen J.-S.; Liao W.-Y.; Shih J.-Y.; Yu C.-J.; KUAN-YU CHEN; Tsai T.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-04-29T05:08:50Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Kuan-Yu Chen;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; KUAN-YU CHEN; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:48Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Kuan-Yu Chen;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; KUAN-YU CHEN; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:47Z |
Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer
|
Chen C.-Y.;Kuan-Yu Chen;Shih J.-Y.;Yu C.-J.; Chen C.-Y.; KUAN-YU CHEN; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T05:08:46Z |
Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer
|
Hsu C.-L.; Tsai T.-H.; Huang C.-K.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Ruan S.-Y.; KUAN-YU CHEN; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-23T05:56:32Z |
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
|
Wu S.-G.;Yu C.-J.;Chih-Hsin Yang;Shih J.-Y.; Wu S.-G.; Yu C.-J.; CHIH-HSIN YANG; Shih J.-Y. |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Chih-Hsin Yang;Cheng A.-L.;Kuo S.-H.; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; CHIH-HSIN YANG; Cheng A.-L.; Kuo S.-H. |
